Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

5  Enrolling
9  Total Trials
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Enrolling
Conditions: Alzheimer's disease
Trial Name
TRAILRUNNER-ALZ 1
Drugs: Remternetug (LY3372993)
Age
60 - 85 years
Phase
III
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Enrolling
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 3
Drugs: Donanemab, LY3002813
Age
65 - 80 years
Phase
III
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Enrolling
Conditions: Alzheimer's disease
Drugs: donanemab
Age
60 - 85 years
Phase
III
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Enrolling
Conditions: Alzheimer's disease
Drugs: donanemab
Age
60 - 85 years
Phase
III
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
Enrolling
Conditions: Gaucher Disease, Type 1
Trial Name
PROCEED
Drugs: LY3884961
Age
18 - 65 years
Phase
II

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
1  Not Yet Enrolling
9  Total Trials
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Not Yet Enrolling
Conditions: Alzheimer's Disease
Drugs: LY3954068, Flortaucipir F18
Age
50 - 85 years
Phase
I
3 
Completed Enrollment
9  Total Trials
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 2
Drugs: Donanemab
Age
60 - 85 years
Phase
III
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
Completed Enrollment
Conditions: Alzheimer's Disease
Drugs: LY3372993
Age
18 - 85 years
Phase
I
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease (PROSPECT-ALZ)
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
PROSPECT-ALZ
Drugs: LY3372689
Age
60 - 85 years
Phase
II